TScan Therapeutics (TCRX) Income from Continuing Operations (2020 - 2026)
TScan Therapeutics' (TCRX) quarterly Income from Continuing Operations came in at 28666000.0 in Q1 2026, up 22.49% year-on-year from 23402572.6 in Q1 2025, and up 10.94% on a QoQ basis from 32186000.0 in Q4 2025.
TScan Therapeutics (TCRX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has 7 years of Income from Continuing Operations data on file, last reported at 28666000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 22.49% year-over-year to 28666000.0 in Q1 2026; TTM through Mar 2026 was 133514000.0, a 8.09% increase from a year earlier, with the FY2025 full-year figure at 219857000.0, down 52.08% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 28666000.0, up from 32186000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for TCRX reached as high as 15097000.0 in Q2 2022 and fell as low as 46733000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 27695588.24 across 5 years, with a median of 28666000.0 in 2026.
- On a YoY basis, Income from Continuing Operations climbed as much as 54.13% in 2022 and fell as far as 104.2% in 2022.
- Year by year, Income from Continuing Operations stood at 19547000.0 in 2022, then fell by 29.2% to 25254000.0 in 2023, then tumbled by 85.05% to 46733000.0 in 2024, then jumped by 31.13% to 32186000.0 in 2025, then climbed by 10.94% to 28666000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 28666000.0 in Q1 2026, 32186000.0 in Q4 2025, and 35710000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 205.99 Mn |
| 10 | TScan Therapeutics | 102.89 Mn | -25.17 Mn | - | -28.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.67 Mn |
| Dec 31, 2025 | -32.19 Mn |
| Sep 30, 2025 | -35.71 Mn |
| Jun 30, 2025 | -36.95 Mn |
| Mar 31, 2025 | -36.98 Mn |
| Dec 31, 2024 | -46.73 Mn |
| Sep 30, 2024 | -29.89 Mn |
| Jun 30, 2024 | -31.66 Mn |
| Mar 31, 2024 | -30.14 Mn |
| Dec 31, 2023 | -25.25 Mn |
| Sep 30, 2023 | -23.00 Mn |
| Jun 30, 2023 | -24.05 Mn |
| Mar 31, 2023 | -22.56 Mn |
| Dec 31, 2022 | -19.55 Mn |
| Sep 30, 2022 | -16.25 Mn |
| Jun 30, 2022 | -15.10 Mn |
| Mar 31, 2022 | -16.16 Mn |
| Dec 31, 2021 | -16.32 Mn |
| Sep 30, 2021 | -25.29 Mn |
| Jun 30, 2021 | -32.91 Mn |